Evaxion A (EVAX) Interest Expenses (2020 - 2026)
Evaxion A posted quarterly Interest Expenses of -$332000.0 for Q1 2026, up 16.37% year-on-year from -$285290.0 in Q1 2025, and up 87.92% on a QoQ basis from -$2.7 million in Q4 2025.
Evaxion A (EVAX) has 7 years of Interest Expenses data on file, last reported at -$332000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses rose 16.37% year-over-year to -$332000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.7 million (down 73.19% YoY), and the FY2025 full-year result was -$5.7 million, down 83.67% from the prior year.
- Interest Expenses for Q1 2026 stood at -$332000.0, up from -$2.7 million in the prior quarter.
- Across five years, Interest Expenses topped out at -$158000.0 in Q1 2022 and bottomed at -$2.7 million in Q4 2025.
- The 5-year median for Interest Expenses is -$397000.0 (2025), against an average of -$728352.9.
- The widest annual swing landed in 2022, when Interest Expenses slumped 949.02%; it then soared 65.98% in 2023.
- A 5-year view of Interest Expenses shows it stood at -$590000.0 in 2022, then plunged by 51.69% to -$895000.0 in 2023, then soared by 48.83% to -$458000.0 in 2024, then slumped by 500.0% to -$2.7 million in 2025, then jumped by 87.92% to -$332000.0 in 2026.
- The last three Interest Expenses figures came in at -$332000.0 (Q1 2026), -$2.7 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 12.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -332,000.00 |
| Mar 31, 2026 | -332,000.00 |
| Dec 31, 2025 | -2.75 Mn |
| Dec 31, 2025 | -2.75 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Jun 30, 2025 | -1.23 Mn |
| Jun 30, 2025 | -1.23 Mn |
| Mar 31, 2025 | -397,000.00 |
| Mar 31, 2025 | -397,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Sep 30, 2024 | -384,000.00 |
| Sep 30, 2024 | -384,000.00 |
| Jun 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -2.04 Mn |
| Mar 31, 2024 | -246,000.00 |
| Mar 31, 2024 | -246,000.00 |
| Dec 31, 2023 | -895,000.00 |
| Dec 31, 2023 | -895,000.00 |
| Sep 30, 2023 | -182,000.00 |
| Sep 30, 2023 | -182,000.00 |
| Jun 30, 2023 | -278,000.00 |
| Jun 30, 2023 | -278,000.00 |
| Mar 31, 2023 | -326,000.00 |
| Mar 31, 2023 | -326,000.00 |
| Dec 31, 2022 | -590,000.00 |
| Dec 31, 2022 | -590,000.00 |
| Sep 30, 2022 | -535,000.00 |
| Sep 30, 2022 | -535,000.00 |
| Jun 30, 2022 | -225,000.00 |
| Jun 30, 2022 | -225,000.00 |
| Mar 31, 2022 | -158,000.00 |
| Mar 31, 2022 | -158,000.00 |
| Dec 31, 2021 | -72,000.00 |
| Dec 31, 2021 | -72,000.00 |
| Sep 30, 2021 | -51,000.00 |
| Sep 30, 2021 | -51,000.00 |
| Jun 30, 2021 | -495,000.00 |
| Jun 30, 2021 | -495,000.00 |
| Mar 31, 2021 | -297,000.00 |
| Mar 31, 2021 | -297,000.00 |
| Dec 31, 2020 | -216,000.00 |
| Dec 31, 2020 | -216,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Jun 30, 2020 | -4,000.00 |
| Jun 30, 2020 | -4,000.00 |
| Mar 31, 2020 | -4,000.00 |
| Mar 31, 2020 | -4,000.00 |